✦ LIBER ✦

Hepatitis C virus kinetics after liver transplantation to study the role of a small molecule inhibitor of viral entry

✍ Scribed by Rowe, Ian A; Armstrong, Matthew; Parker, Richard; Guo, Kathy; Adams, David; Balfe, Peter; Mutimer, David; McKeating, Jane A

Book ID: 123441142
Publisher: The Lancet
Year: 2013
Tongue: English
Weight: 42 KB
Volume: 381
Category: Article
ISSN: 0140-6736
DOI: 10.1016/S0140-6736(13)60535-8

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Liver transplantation as a model to bett

Liver transplantation as a model to better understand the cell entry of hepatitis C virus

✍ Cyril Féray 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 369 KB

777 ROLE OF RAPAMYCIN AS MTOR INHIBITOR

777 ROLE OF RAPAMYCIN AS MTOR INHIBITOR IN VITRO AND ITS USE IN THE TREATMENT OF RECURRENT HEPATITIS C AFTER LIVER TRANSPLANTATION

✍ J.A. Del Campo; A. Bonnel; M. Cuaresma; O. Shaked; M. García-Valdecasas; K. Raje 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 164 KB

Role of mannose-binding lectin-2 polymor

Role of mannose-binding lectin-2 polymorphism in the development of acute cellular rejection after transplantation for hepatitis C virus-induced liver disease

✍ D. Eurich; S. Boas-Knoop; A. Yahyazadeh; R. Neuhaus; R. Somasundaram; M. Ruehl; 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 152 KB

Hepatitis C virus–infected women have a

Hepatitis C virus–infected women have a higher risk of advanced fibrosis and graft loss after liver transplantation than men

✍ Jennifer C. Lai; Elizabeth C. Verna; Robert S. Brown Jr.; Jacqueline G. O'Leary; 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 174 KB 👁 2 views

In natural history studies of hepatitis C virus (HCV) infection, women have a lower risk of disease progression to cirrhosis. Whether female sex influences outcomes of HCV in the posttransplantation setting is unknown. All patients transplanted for HCV-related liver disease from 2002-2007 at five Un

PHOENIX: A randomized controlled trial o

PHOENIX: A randomized controlled trial of peginterferon alfa-2a plus ribavirin as a prophylactic treatment after liver transplantation for hepatitis C virus

✍ Natalie Bzowej; David R. Nelson; Norah A. Terrault; Gregory T. Everson; Lichen L 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 249 KB 👁 2 views

The efficacy, tolerability, and safety of the prophylactic treatment of hepatitis C virus (HCV) after liver transplantation (LT) with peginterferon alfa-2a and ribavirin are not known. LT recipients with HCV were randomized to peginterferon alfa-2a/ribavirin treatment or observation 10 to 26 weeks p

T-23 Poor adherence to pegylated interfe

T-23 Poor adherence to pegylated interferon and ribavirin is a major concern in the treatment of hepatitis C after liver transplantation: Evidence from the AISF RECOLT-C study group

✍ D. Di Paolo; F.R. Ponziani; S. Fagiuoli; R. Viganò; R.M. Iemmolo; M.F. Donato; M 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 48 KB